Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeLuRide-008: EIK1001 plus pembrolizumab and chemotherapy in stage IV non-small cell lung cancer
2025-525013-23-00Phase 2Authorised
- Sponsor
- Eikon Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing EIK1001 combination arm with Placebo control arm (2 arms). Primary endpoints: Progression-free survival, Overall survival and 3 more. Planned start Jul 2026; status: authorised.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-525013-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525013-23-00.